Literature DB >> 12610748

Determinants for drug prescribing to children below the minimum licensed age.

Geert W 't Jong1, Ingo A Eland, Miriam C J M Sturkenboom, John N van den Anker, Bruno H C Stricker.   

Abstract

OBJECTIVES: In the light of the undesired effects that unlicensed and off-label drug use might have, it is necessary to study the determinants affecting the prescribing of such drugs. Prescription of drugs to children younger than the minimum licensed age may carry the highest risk of adverse reactions. To obtain insight into the factors that affect prescription of drugs to children below the minimum licensed age, we conducted a population-based case-control study.
METHODS: The case-control study was nested in a cohort of 13,426 children aged 0-16 years, who were registered in the Integrated Primary Care Information (IPCI) project, a longitudinal observational general practitioners' database in the Netherlands. "Cases" were children who received a drug prescription for which they were below the minimum licensed age. To each case we matched up to four controls based on GP practice and patient age. As potential risk factors we evaluated the use of health care resources, and acute and chronic morbidity.
RESULTS: We identified 447 cases who were matched to 1355 controls. The cases consulted their GPs significantly more often during the preceding half year, had more drug prescriptions, and had more specialist referrals than the controls. Respiratory diseases were the most important determinants for the prescription of drugs to children below the minimum licensed age. In adolescents, migraine and other headaches were the most important reasons.
CONCLUSIONS: This study showed that children suffering from respiratory disease or migraine have the highest risk of receiving a drug prescription for which the patient is below the minimum licensed age. Regulatory authorities and the pharmaceutical industry should be stimulated to improve the evaluation of drug efficacy and safety in children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610748     DOI: 10.1007/s00228-002-0554-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Unlicensed and off label drug use in neonates.

Authors:  S Conroy; J McIntyre; I Choonara
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-03       Impact factor: 5.747

2.  [The incidence of prescriptions without marketing product license in a neonatal intensive care unit].

Authors:  S Avenel; A Bomkratz; G Dassieu; J C Janaud; C Danan
Journal:  Arch Pediatr       Date:  2000-02       Impact factor: 1.180

3.  Pharmacokinetic and pharmacodynamic data collection in children and neonates. A quiet frontier.

Authors:  J T Gilman; P Gal
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

4.  Postmarketing surveillance based on electronic patient records: the IPCI project.

Authors:  A E Vlug; J van der Lei; B M Mosseveld; M A van Wijk; P D van der Linden; M C Sturkenboom; J H van Bemmel
Journal:  Methods Inf Med       Date:  1999-12       Impact factor: 2.176

5.  Drug prescribing among Danish children: a population-based study.

Authors:  H Madsen; M Andersen; J Hallas
Journal:  Eur J Clin Pharmacol       Date:  2001-05       Impact factor: 2.953

6.  Unlicensed and off label drug use in paediatric wards: prospective study.

Authors:  S Turner; A Longworth; A J Nunn; I Choonara
Journal:  BMJ       Date:  1998-01-31

7.  Using ICPC in a computer-based primary care information system.

Authors:  M S Klinkman; L A Green
Journal:  Fam Med       Date:  1995 Jul-Aug       Impact factor: 1.756

8.  Use of "off-label" and unlicensed drugs in paediatric intensive care unit.

Authors:  S Turner; A Gill; T Nunn; B Hewitt; I Choonara
Journal:  Lancet       Date:  1996-02-24       Impact factor: 79.321

9.  Paediatric drug prescribing. A comparison of Tenerife (Canary Islands, Spain) and Sweden.

Authors:  E J Sanz; U Bergman; M Dahlström
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

10.  Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study.

Authors:  S Turner; A J Nunn; K Fielding; I Choonara
Journal:  Acta Paediatr       Date:  1999-09       Impact factor: 2.299

View more
  7 in total

Review 1.  Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature.

Authors:  Jennifer Mason; Munir Pirmohamed; Tony Nunn
Journal:  Eur J Clin Pharmacol       Date:  2011-07-22       Impact factor: 2.953

Review 2.  Two decades of off-label prescribing in children: a literature review.

Authors:  Shamala Balan; Mohamed Azmi Ahmad Hassali; Vivienne S L Mak
Journal:  World J Pediatr       Date:  2018-09-14       Impact factor: 2.764

3.  Clinical trials research in pediatrics: strategies for effective collaboration between investigator sites and the pharmaceutical industry.

Authors:  Andrew Bush
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 4.  A literature review on off-label drug use in children.

Authors:  Chiara Pandolfini; Maurizio Bonati
Journal:  Eur J Pediatr       Date:  2005-05-24       Impact factor: 3.183

5.  The Unlicensed and Off-label Prescription of Medications in General Paediatric Ward: An Observational Study.

Authors:  Alícia Dorneles Dornelles; Lisiane Hoff Calegari; Lucian de Souza; Patrícia Ebone; Tiago Silva Tonelli; Clarissa Gutierrez Carvalho
Journal:  Curr Pediatr Rev       Date:  2019

6.  [Drug prescriptions study in the outpatient setting: assessment of off-label uses in children].

Authors:  Encarnación Blanco-Reina; M Auxiliadora Vega-Jiménez; Ricardo Ocaña-Riola; Elisa Isabel Márquez-Romero; Inmaculada Bellido-Estévez
Journal:  Aten Primaria       Date:  2014-10-23       Impact factor: 1.137

7.  Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital.

Authors:  Jennifer R Bellis; Jamie J Kirkham; Anthony J Nunn; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.